A Study of Fycompa (Perampanel) in Korean Participants

Inclusion Criteria: 1. Participants with approved indication for Fycompa (Perampanel) in Korea as follows: * Monotherapy (film-coated tablets) o 4 years and older Partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy * Adjunctive therapy (film-coated tablets \& oral suspension) * 4 years and older Partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy * 7 years and older Primary generalized tonic-clonic seizures: therapy for treatment of primary generalized tonic-clonic seizures in participants with idiopathic generalized epilepsy 2. Participants who have written consent for use of personal and medical information for the study purpose Exclusion Criteria: 1. Hypersensitivity to the active substance or to any of the excipients of this medicine 2. In case of Fycompa film-coated tablets, Fycompa tablets contains lactose; therefore, participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. In case of Fycompa oral suspension, Fycompa suspension contains sorbitol; therefore, participants with rare hereditary problems of fructose intolerance should not take this medicine. 3. Other participants judged to be inadequate to participate in the study by doctor